Frede Donskov

List of Publications by Year in Descending Order

212 papers	14,933 citations	47 h-index	121 g-index
235 ext. papers	19,058 ext. citations	5.9 avg, IF	6.14 L-index

#	Paper	IF	Citations
212	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2022**, 40, 317-317	2.2	0
211	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2022**, 40, 308-308	2.2	0
210	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. *Journal of Clinical Oncology*, **2022**, 40, 310-310	2.2	
209	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma.. *European Radiology*, **2022**, 1	8	0
208	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. *European Urology*, **2021**, 81, 266-266	10.2	4
207	Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. *Acta Oncologica*, **2021**, 1-6	3.2	1
206	Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. *New England Journal of Medicine*, **2021**, 385, 2036-2046	59.2	41
205	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma. *Scientific Reports*, **2021**, 11, 19659	4.9	
204	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *European Urology*, **2021**, 79, 334-338	10.2	11
203	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2021**, 39, 1029-1039	2.2	43
202	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2021**, 39, 1020-1028	2.2	26
201	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. *BJU International*, **2021**, 128, 254-261	5.6	
200	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2021**, 39, 4554-4554	2.2	0
199	First-line therapy in patients with metastatic renal cell carcinoma (mRCC): Results from consecutive patients over 25 years in a single institution.. *Journal of Clinical Oncology*, **2021**, 39, e16574-e16574	2.2	
198	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. *JAMA Oncology*, **2021**, 7, 773-775	13.4	6
197	Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. *Journal of Geriatric Oncology*, **2021**, 12, 827-833	3.6	6
196	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. *Journal of Geriatric Oncology*, **2021**, 12, 820-826	3.6	6

195	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. *European Radiology Experimental*, **2021**, 5, 32	4.5	1
194	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. *European Urology*, **2021**, 79, 659-662	10.2	30
193	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 78-86	12.9	60
192	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. *European Urology Oncology*, **2021**, 4, 102-111	6.7	15
191	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. *JAMA Network Open*, **2021**, 4, e2021869	10.4	23
190	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. *European Journal of Cancer*, **2021**, 151, 115-125	7.5	5
189	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. *Clinical Genitourinary Cancer*, **2021**, 19, 354-361	3.3	1
188	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. *Cardio-Oncology*, **2021**, 7, 27	2.8	5
187	661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *Annals of Oncology*, **2021**, 32, S685-S687	10.3	5
186	Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. *Clinical Epidemiology*, **2021**, 13, 871-882	5.9	1
185	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer Medicine*, **2021**, 10, 1212-1221	4.8	4
184	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.. *JAMA Oncology*, **2021**,	13.4	7
183	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.. *American Journal of Roentgenology*, **2021**,	5.4	1
182	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. *Journal of Ovarian Research*, **2020**, 13, 59	5.5	3
181	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. *JCO Global Oncology*, **2020**, 6, 293-306	3.7	2
180	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology Oncology*, **2020**, 3, 530-539	6.7	14
179	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. *Oncologist*, **2020**, 25, 422-430	5.7	5
178	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. *Acta Oncologica*, **2020**, 59, 652-659	3.2	13

177	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. *European Urology*, **2020**, 78, 615-623	10.2	19
176	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2020**, 26, 2506-2514	12.9	10
175	Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease associated renal cell carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 5003-5003	2.2	25
174	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. *Journal of Clinical Oncology*, **2020**, 38, 5024-5024	2.2	8
173	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. *Journal of Clinical Oncology*, **2020**, 38, 5034-5034	2.2	3
172	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. *Journal of Clinical Oncology*, **2020**, 38, 5063-5063	2.2	3
171	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.. *Journal of Clinical Oncology*, **2020**, 38, 5068-5068	2.2	2
170	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.. *Journal of Clinical Oncology*, **2020**, 38, 5069-5069	2.2	4
169	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 5071-5071	2.2	2
168	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. *Journal of Clinical Oncology*, **2020**, 38, 608-608	2.2	5
167	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2020**, 38, 609-609	2.2	32
166	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2020**, 38, 617-617	2.2	19
165	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2020**, 38, 639-639	2.2	1
164	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2020**, 38, 642-642	2.2	3
163	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2020**, 38, 684-684	2.2	2
162	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. *Journal of Clinical Oncology*, **2020**, 38, 701-701	2.2	
161	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. *Journal of Clinical Oncology*, **2020**, 38, 5070-5070	2.2	
160	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. *Kidney Cancer*, **2020**, 4, 29-39	0.6	1

159	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. *European Journal of Cancer*, **2020**, 126, 1-10	7.5	13
158	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2020**, 18, e350-e359	3.3	1
157	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. *Translational Oncology*, **2020**, 13, 100829	4.9	4
156	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial **2020**, 8,		68
155	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. *Cancer*, **2020**, 126, 4156-4167	6.4	66
154	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*, **2020**, 5, e001079	6	109
153	Blood natural killer cells during treatment in recurrent ovarian cancer. *Acta Oncologica*, **2020**, 59, 1365-1373	3.1	2
152	18F-FDG Uptake in a Mesonephric Carcinoma. *Clinical Nuclear Medicine*, **2020**, 45, 696-699	1.7	
151	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. *Annals of Oncology*, **2020**, 31, S559-S560	10.3	12
150	Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3). *Clinical Epidemiology*, **2020**, 12, 807-814	5.9	2
149	Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. *Clinical Genitourinary Cancer*, **2020**, 18, 62-68.e2	3.3	7
148	Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma. *Acta Oncologica*, **2020**, 59, 13-19	3.2	2
147	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. *European Urology*, **2019**, 76, 861-867	10.2	39
146	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet, The*, **2019**, 393, 2404-2415	40	490
145	Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. *Clinical Genitourinary Cancer*, **2019**, 17, 254-259	3.3	4
144	Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Current Oncology*, **2019**, 26, e175-e179	2.8	13
143	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 1370-1385	21.7	343
142	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A. *Annals of Oncology*, **2019**, 30, v381-v382	10.3	5

141	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). *Annals of Oncology*, **2019**, 30, v396	10.3	3
140	Tissue immune response in epithelial ovarian carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 2625-2625	2.2	1
139	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. *Journal of Clinical Oncology*, **2019**, 37, 4512-4512	2.2	21
138	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. *Journal of Clinical Oncology*, **2019**, 37, 4513-4513	2.2	49
137	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. *Journal of Clinical Oncology*, **2019**, 37, 4569-4569	2.2	18
136	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. *Journal of Clinical Oncology*, **2019**, 37, 4570-4570	2.2	12
135	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. *Journal of Clinical Oncology*, **2019**, 37, 546-546	2.2	35
134	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2	6
133	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 581-581	2.2	10
132	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2019**, 37, 584-584	2.2	4
131	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. *Journal of Clinical Oncology*, **2019**, 37, 610-610	2.2	1
130	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. *Journal of Clinical Oncology*, **2019**, 37, 4578-4578	2.2	
129	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. *Journal of Clinical Oncology*, **2019**, 37, 4577-4577	2.2	1
128	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology Oncology*, **2019**, 2, 643-648	6.7	19
127	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. *Clinical Genitourinary Cancer*, **2019**, 17, 65-71	3.3	6
126	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. *Clinical Cancer Research*, **2019**, 25, 1165-1173	12.9	10
125	Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. *Clinical Genitourinary Cancer*, **2019**, 17, e32-e37	3.3	7
124	A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. *Acta Oncologica*, **2018**, 57, 589-594	3.2	13

123	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. *Clinical Cancer Research*, **2018**, 24, 3005-3013	12.9	37
122	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2018**, 378, 1277-1290	59.2	2064
121	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *European Urology*, **2018**, 73, 62-68	10.2	95
120	Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. *Acta Oncologica*, **2018**, 57, 522-527	3.2	8
119	Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician. *Oncology and Therapy*, **2018**, 6, 1-7	2.7	2
118	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). *Kidney Cancer*, **2018**, 2, 31-36	0.6	6
117	Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. *Acta Oncologica*, **2018**, 57, 1580-1585	3.2	6
116	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. *Journal of Clinical Oncology*, **2018**, 36, 4500-4500	2.2	65
115	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2018**, 36, 4511-4511	2.2	11
114	Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.. *Journal of Clinical Oncology*, **2018**, 36, 576-576	2.2	1
113	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). *Journal of Clinical Oncology*, **2018**, 36, 578-578	2.2	140
112	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2018**, 36, 581-581	2.2	3
111	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2018**, 36, 615-615	2.2	2
110	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. *Journal of Clinical Oncology*, **2018**, 36, 667-667	2.2	
109	Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients. *British Journal of Radiology*, **2018**, 91, 20160795	3.4	8
108	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. *Journal of Clinical Oncology*, **2018**, 36, 757-764	2.2	33
107	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. *Annals of Oncology*, **2018**, 29, viii315	10.3	2
106	Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. *Annals of Oncology*, **2018**, 29, viii309	10.3	7

105	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. *Annals of Oncology*, **2018**, 29, viii308	10.3	2
104	Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. *Annals of Oncology*, **2018**, 29, 2098-2104	10.3	23
103	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology*, **2017**, 71, 204-209	10.2	52
102	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2017**, 15, 403-410.e2	2.3	12
101	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. *European Urology*, **2017**, 72, 962-971	10.2	136
100	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. *European Urology*, **2017**, 72, 368-376	10.2	148
99	Characterizing the outcomes of metastatic papillary renal cell carcinoma. *Cancer Medicine*, **2017**, 6, 902-909	4	28
98	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. *European Journal of Cancer*, **2017**, 81, 9-16	7.5	10
97	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). *Kidney Cancer*, **2017**, 1, 41-47	0.6	9
96	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2017**, 35, 3916-3923	2.2	204
95	Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma. *Investigative Radiology*, **2017**, 52, 103-110	10.1	13
94	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. *European Urology*, **2017**, 71, 970-978	10.2	12
93	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. *Journal of Clinical Oncology*, **2017**, 35, 4507-4507	2.2	21
92	Pazopanib exposure-response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy.. *Journal of Clinical Oncology*, **2017**, 35, 4564-4564	2.2	6
91	Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2017**, 35, 498-498	2.2	3
90	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 517-517	2.2	2
89	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 4570-4570	2.2	
88	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. *Journal of Clinical Oncology*, **2017**, 35, e16065-e16065	2.2	

87	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 4578-4578	2.2	1
86	Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. *BJU International*, **2016**, 117, 110-7	5.6	42
85	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 917-927	21.7	580
84	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. *European Urology*, **2016**, 70, 358-64	10.2	112
83	A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. *Acta Oncologica*, **2016**, 55, 341-8	3.2	12
82	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2016**, 34, 4506-4506	2.2	1
81	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. *Journal of Clinical Oncology*, **2016**, 34, 4509-4509	2.2	9
80	A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1.. *Journal of Clinical Oncology*, **2016**, 34, 4563-4563	2.2	4
79	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. *Journal of Clinical Oncology*, **2016**, 34, 4570-4570	2.2	1
78	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2016**, 34, 498-498	2.2	15
77	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2016**, 34, 499-499	2.2	7
76	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2016**, 34, 544-544	2.2	1
75	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. *Journal of Clinical Oncology*, **2016**, 34, 552-552	2.2	0
74	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. *Journal of Clinical Oncology*, **2016**, 34, 534-534	2.2	
73	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2016**, 34, 503-503	2.2	
72	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. *Journal of Clinical Oncology*, **2016**, 34, 4554-4554	2.2	
71	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. *Journal of Clinical Oncology*, **2016**, 34, 4510-4510	2.2	
70	The database of the Danish Renal Cancer Group. *Clinical Epidemiology*, **2016**, 8, 725-729	5.9	7

69	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *New England Journal of Medicine*, **2016**, 375, 2246-2254	59.2	450
68	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Journal of Cancer*, **2016**, 65, 102-8	7.5	51
67	Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Clinical Genitourinary Cancer*, **2015**, 13, e79-85	3.3	59
66	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. *Lancet Oncology, The*, **2015**, 16, 293-300	21.7	229
65	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2015**, 373, 1814-23	59.2	762
64	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2015**, 373, 1803-13	59.2	3725
63	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. *British Journal of Cancer*, **2015**, 113, 1571-80	8.7	76
62	Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. *European Urology*, **2015**, 68, 516-22	10.2	9
61	Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. *European Urology*, **2015**, 68, 506-15	10.2	27
60	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. *Clinical Genitourinary Cancer*, **2015**, 13, 150-5	3.3	9
59	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. *Journal of Clinical Oncology*, **2015**, 33, 430-430	2.2	2
58	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2015**, 33, e15578-e15578	2.2	0
57	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. *Journal of Clinical Oncology*, **2015**, 33, 4558-4558	2.2	
56	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *European Urology*, **2014**, 65, 577-84	10.2	166
55	Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology*, **2014**, 66, 704-10	10.2	282
54	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. *Clinical Genitourinary Cancer*, **2014**, 12, 335-40	3.3	7
53	The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. *European Urology*, **2014**, 65, 723-30	10.2	59
52	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. *Clinical Genitourinary Cancer*, **2014**, 12, e127-31	3.3	20

51	Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. *European Urology*, **2014**, 65, 1086-92	10.2	56
50	Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments. *The Journal of Oncopathology*, **2014**, 2, 1-9		3
49	Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. *PLoS ONE*, **2014**, 9, e98259	3.7	189
48	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. *British Journal of Cancer*, **2014**, 110, 1917-22	8.7	54
47	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. *Annals of Oncology*, **2014**, 25, 149-54	10.3	99
46	Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1. *Investigative Radiology*, **2014**, 49, 601-7	10.1	18
45	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. *Clinical Genitourinary Cancer*, **2014**, 12, 354-8	3.3	20
44	Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. *European Journal of Cancer*, **2014**, 50, 553-62	7.5	59
43	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2014**, 32, 396-396	2.2	7
42	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. *Journal of Clinical Oncology*, **2014**, 32, 398-398	2.2	6
41	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. *Targeted Oncology*, **2013**, 8, 203-209	5	45
40	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. *Cancer*, **2013**, 119, 2999-3006	6.4	144
39	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. *Journal of Translational Medicine*, **2013**, 11, 189	8.5	24
38	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncology, The* , **2013**, 14, 141-8	21.7	598
37	Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. *Journal of Oral and Maxillofacial Surgery*, **2013**, 71, 1532-40	1.8	48
36	Immunomonitoring and prognostic relevance of neutrophils in clinical trials. *Seminars in Cancer Biology*, **2013**, 23, 200-7	12.7	196
35	Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. *Lung Cancer*, **2013**, 81, 130-7	5.9	79
34	Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. *Immunopharmacology and Immunotoxicology*, **2013**, 35, 487-96	3.2	4

33	Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. *British Journal of Cancer*, **2013**, 108, 2116-22	8.7	77
32	Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.. *Journal of Clinical Oncology*, **2013**, 31, 4565-4565	2.2	4
31	First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2013**, 31, 4586-4586	2.2	1
30	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2013**, 31, 394-394	2.2	1
29	Metastatic non□lear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. *Journal of Clinical Oncology*, **2013**, 31, 396-396	2.2	
28	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2013**, 31, e15518-e15518	2.2	
27	Tumor-associated CD66b+ neutrophil and CD8+ lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments.. *Journal of Clinical Oncology*, **2013**, 31, 5532-5532	2.2	
26	Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.. *Journal of Clinical Oncology*, **2013**, 31, 4578-4578	2.2	
25	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. *Lancet Oncology, The*, **2012**, 13, 927-35	21.7	104
24	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. *Cancer*, **2012**, 118, 2476-85	6.4	180
23	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. *Annals of Oncology*, **2012**, 23, 1549-55	10.3	108
22	Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC). *Annals of Oncology*, **2012**, 23, ix259	10.3	4
21	Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage.. *Journal of Clinical Oncology*, **2012**, 30, e21110-e21110	2.2	
20	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. *Journal of Clinical Oncology*, **2012**, 30, 4536-4536	2.2	
19	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. *Journal of Clinical Oncology*, **2012**, 30, 4538-4538	2.2	
18	1141 POSTER Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC). *European Journal of Cancer*, **2011**, 47, S136	7.5	10
17	Wildtype p53-specific antibody and T-cell responses in cancer patients. *Journal of Immunotherapy*, **2011**, 34, 629-40	5	9
16	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. *Cancer*, **2011**, 117, 2637-42	6.4	64

15	Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. *British Journal of Cancer*, **2010**, 102, 867-72	8.7	67
14	Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. *Journal of Clinical Oncology*, **2009**, 27, 4709-17	2.2	321
13	Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. *Clinical Cancer Research*, **2009**, 15, 1052-8	12.9	72
12	Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. *BJU International*, **2008**, 101 Suppl 4, 41-4	5.6	14
11	Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. *Danish Medical Bulletin*, **2007**, 54, 249-65		7
10	Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2006**, 24, 1997-2005	2.2	240
9	Monocytes and neutrophils as Rbad guysR for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial. *British Journal of Cancer*, **2006**, 94, 218-26	8.7	58
8	Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. *British Journal of Cancer*, **2005**, 93, 757-62	8.7	18
7	Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. *Clinical Cancer Research*, **2004**, 10, 7911-6	12.9	7
6	In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma. *British Journal of Cancer*, **2004**, 90, 626-31	8.7	10
5	Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. *Cancer Immunology, Immunotherapy*, **2004**, 53, 729-39	7.4	40
4	Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. *Anticancer Research*, **2003**, 23, 537-42	2.3	10
3	Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. *British Journal of Cancer*, **2002**, 87, 194-201	8.7	41
2	Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. *Annals of Oncology*, **2002**, 13, 441-9	10.3	20
1	Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. *Natural Immunity*, **1996**, 15, 134-46		6